Amlodipine

證據等級: L5

預測適應症: 10 個

Amlodipine: From Hypertension to Recurrent Intracerebral Hemorrhage Prevention

One-Sentence Summary

Amlodipine is a long-acting dihydropyridine calcium channel blocker (CCB) conventionally used for blood pressure control. TxGNN generated 10 candidate new indications for this drug; among them, secondary prevention of recurrent intracerebral hemorrhage (ICH) via intensive triple-pill blood pressure control stands out as the only candidate backed by real clinical evidence — 6 clinical trials (including one completed Phase 3 RCT, n=1,671) and 8 publications. The other 9 predicted indications range from weak (case-report level) to essentially unsupported (TxGNN score only, no trials or literature) and are not recommended for further action at this time.

Quick Overview

Item	Content
Original Indication	Hypertension (CCB class use — no formal TFDA-approved indication text is available in this dataset)
Predicted New Indication	Recurrent Intracerebral Hemorrhage (secondary prevention, intensive BP control)
TxGNN Prediction Score	99.79% (this candidate ranked 10th of 10 by raw TxGNN score, but has the strongest actual evidence)
Evidence Level	L1
Germany Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for amlodipine is not available in this evidence pack. Based on information embedded in the trial/literature rationale, amlodipine is a dihydropyridine calcium channel blocker that lowers blood pressure by reducing peripheral vascular resistance and cardiac afterload. This is a well-established antihypertensive mechanism rather than a novel one.

The link to ICH is not a mechanistic leap but a direct extension of standard-of-care blood pressure management: intensive BP control is the primary modifiable risk factor for ICH recurrence. The TRIDENT trial (NCT02699645, Phase 3, completed, n=1,671) specifically tested a fixed-dose "Triple Pill" combination (including an amlodipine-class CCB) against standard care in patients with prior ICH, evaluating time to recurrent stroke. A follow-on trial (NCT07458880, actively recruiting, n=140) is now testing a TRICH-score-guided triple antihypertensive strategy in the same population.

This is best understood as a repositioning within the same pharmacological class and mechanism (BP lowering) rather than a mechanistically novel indication — amlodipine's role here is as a component of combination therapy, not a standalone new use.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02699645	Phase 3	Completed	1,671	TRIDENT main trial: fixed-dose triple-pill BP-lowering strategy (incl. amlodipine-class CCB) vs. standard care for preventing recurrent stroke after ICH — directly relevant, largest and most rigorous trial in this set
NCT07458880	N/A	Recruiting	140	TRICH-score-guided triple antihypertensive medication for BP control after ICH
NCT03264352	Phase 4	Recruiting	11,414	High-normal BP intervention in type 2 diabetics — cardiovascular/cerebrovascular risk factor modification, not ICH-specific
NCT00134160	Phase 4	Completed	1,000	High-dose ARB monotherapy vs. ARB+CCB combination therapy in elderly hypertensive Japanese patients at high CV risk
NCT03785067	Phase 3	Terminated	1	TRIDENT cognitive sub-study — terminated, negligible enrollment
NCT03783754	N/A	Terminated	4	TRIDENT MRI sub-study — terminated, negligible enrollment

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34994269	2022	RCT (trial design/protocol)	Int J Stroke	Rationale and design of the TRIDENT trial evaluating single-pill combination BP-lowering (incl. amlodipine) for ICH secondary prevention
14717341	2003	RCT (CASE-J)	Hypertens Res	Rationale/design of a large RCT comparing ARB vs. CCB-based regimens for cardiovascular event reduction in high-risk hypertensives
23053838	2013	Review	Neurol Sci	Role of β-blockers vs. other antihypertensives (context for BP agent selection) in acute hypertensive ICH outcomes
17077518	2006	Cohort	Biol Pharm Bull	Long-acting dihydropyridine CCB (benidipine) improves cerebral blood flow autoregulation in hypertensive rats — supportive mechanistic context
3154329	1988	Review	Cardiovasc Drugs Ther	Overview of CCB antihypertensive mechanism and use in severe hypertension
19299323	2009	Case Report	Ann Pharmacother	Probable amlodipine-induced angioedema in a patient with hemorrhagic stroke — safety signal
26698202	2015	Case Report	BMJ Case Rep	PRES after rapid antihypertensive withdrawal in a patient with prior ICH
37489780	2024	Case Report	Curr Drug Saf	Tizanidine-induced hypotension in stroke patients on antihypertensives — general polypharmacy caution, not amlodipine-specific

Germany Market Information

Amlodipine is currently not marketed in Germany and no marketing authorizations are recorded in this dataset (0 licenses). No approved indication text is therefore available to cite.

Safety Considerations

Formal safety fields (key warnings, contraindications, drug-drug interaction database) contain no data in this evidence pack.

Signal identified in literature review: A case report (PMID 19299323) describes probable amlodipine-induced angioedema in a patient with hemorrhagic stroke — relevant given the proposed post-ICH population and warrants monitoring.
Beyond this, please refer to the package insert for safety information once available.

Additional TxGNN Predictions (Lower Evidence — Not Prioritized)

For completeness, the other 9 candidates from this evidence pack are summarized below. None currently meet the bar for further action (evidence level L3–L5, mostly "Hold").

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation	Note
1	Brain stem infarction	99.94%	L5	Hold	No trials or literature; pure model inference
2	Pulmonary hypertension (lung disease/hypoxia)	99.91%	L5	Hold	Literature is generic hypoxia biology, not amlodipine-specific; CCBs may theoretically worsen hypoxic pulmonary vasoconstriction
3	Pulmonary hypertension (unclear mechanism)	99.91%	L5	Hold	No evidence at all
4	Malignant renovascular hypertension	99.90%	L4	Research Question	Only 2 pediatric case reports; mechanistically plausible (standard CCB use in severe hypertension)
5	Malignant hypertensive renal disease	99.90%	L5	Hold	No evidence
6	Cerebral artery occlusion	99.89%	L3	Research Question	Preclinical (rodent MCAO) neuroprotection data; human trials are BP-management context, not disease-specific
7	Braddock syndrome	99.88%	L5	Hold	No known CCB-related pathophysiology; likely false positive
8	MRI-defined brain infarct	99.86%	L4	Hold	Single trial, status Unknown, not amlodipine-specific
9	ABri amyloidosis	99.84%	L5	Hold	No known mechanistic link; likely false positive

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The recurrent intracerebral hemorrhage indication is supported by a completed Phase 3 RCT (TRIDENT, n=1,671) directly testing an amlodipine-containing triple-pill regimen, plus an actively recruiting confirmatory trial (NCT07458880). This is real, class-appropriate evidence — but it reflects amlodipine's established antihypertensive role within a combination strategy, not a standalone novel mechanism, and a safety signal (angioedema in stroke patients) needs monitoring.

To proceed, the following is needed:

TFDA/German product label data (warnings, contraindications, DDI) — currently a blocking data gap (DG001)
Formal mechanism-of-action documentation (DG002)
Formal confirmation of amlodipine's originally approved indication text, given the absence of Germany licensing records
Monitoring plan for angioedema risk in post-ICH patients
The 9 lower-evidence candidates should not advance without new trial or literature data; re-screen periodically for updates
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.